The global healthcare and biotechnology industry is witnessing strong momentum in immunotherapy research, particularly in cancer treatment solutions. Anti-PD-1 antibodies have emerged as a transformative class of immunotherapeutic agents that enhance the immune system’s ability to identify and destroy cancer cells. Growing cancer prevalence, increasing investment in biologics research,...